Double-Blind Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole in Complicated Urinary Tract Infections
The clinical efficacy and safety of cefpiramide (SM-1652, CPM) were compared with those of cefmetazole (CMZ) in patients with complicated urinary tract infections by double-blind method. Either of CPM or CMZ was assigned to each patient at random. Administration was performed by intravenous drip inf...
Gespeichert in:
| Veröffentlicht in: | Kansenshogaku Zasshi 1983/08/20, Vol.57(8), pp.695-723 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 723 |
|---|---|
| container_issue | 8 |
| container_start_page | 695 |
| container_title | Kansenshogaku Zasshi |
| container_volume | 57 |
| creator | ISHIGAMI, Joji KAMIDONO, Sadao ARAKAWA, Sohichi KATAOKA, Nobumasa NAKANO, Koji HARADA, Masuyoshi HIROOKA, Kyubei SHIMATANI, Nobori ITANI, Atsushi MATSUSHITA, Masami HIKOSAKA, Koji MATSUMOTO, Osamu OHYA, Kakuyoshi ITO, Noboru HARADA, Kenji KIYOTA, Toshikazu SAITO, Hiroshi KITANO, Yoshihiko TAKAHASHI, Yasumasa HARA, Shinji OHMAE, Hiroshi OHBE, Toru YASUNO, Hirohiko KATAOKA, Nobuo OKUDAIRA, Hiroshi KAWABATA, Gaku OHSHIMA, Hideo DEN, Shusoo TOMIOKA, Osamu TADERA, Shigenori UEHARAGUCHI, Hiroshi ODA, Yoshinori YAMAZAKI, Hiroshi TAKADA, Kenichi OKADA, Yasunaga HINENO, Suguru KURODA, Yasuji MOMOSE, Shunro TAKEI, Mineo KUMAZAWA, Joichi NAKAMUTA, Seiichi SAKAMOTO, Kimitaka OSHIMA, Kazuhiro ISHIZAWA, Nobuyuki OSADA, Yukio HARA, Sanshin EMOTO, Kanichi HIRATA, Kozo MORITA, Ichikiro MINODA, Kunihiro HIRANO, Haruka NAGAYOSHI, Hiroyuki SATO, Shinichi OMOTO, Tetsuo YAGI, Hiroaki HIRATA, Hiroshi ANDO, Sadamu IWATSUBO, Eiji KOMINE, Shinichiro OGAWA, Nobuya |
| description | The clinical efficacy and safety of cefpiramide (SM-1652, CPM) were compared with those of cefmetazole (CMZ) in patients with complicated urinary tract infections by double-blind method. Either of CPM or CMZ was assigned to each patient at random. Administration was performed by intravenous drip infusion for a fixed period of 5 days and daily dosage was fixed at each 2 g for CPM or CMZ. Out of 249 patients, 211 patients (CPM; 110 cases, CMZ: 101 cases) were evaluated for clinical efficacy by the criteria proposed by UTI committee in Japan. It was indicated that there was no significant difference between the two groups (CPM group and CMZ group) regarding the all of background factors. Overall clinical effectiveness; Response was excellent in 27.7%, moderate in 39.8% and poor in 32.5% of the CPM group, excellent in 17.3%, moderate in 33.3% and poor in 49.3% of the CMZ group. Response rate inclusive of excellent and moderate was significantly higher in the CPM group than in the CMZ (p |
| doi_str_mv | 10.11150/kansenshogakuzasshi1970.57.695 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80846106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80846106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3105-8468070b55999cf528712f75f185ca4b1d701a6e458678a0f711a189902d64583</originalsourceid><addsrcrecordid>eNp9UEtv1DAQthCorEp_ApJPPA5ZPEkc2ycEAUqlIg7bStyiiTPumuax2Ami_fW43dXe4DIjzfcafYy9BrEGACne3eIYaYzb6QZvl3uMcevBKLGWal0Z-YStQOsyk5X58ZStRKFVJg3Ac3YWo2-FEKYUucxP2ElV5qLUxYr9-TQtbU_Zx96PHa-nYYcBZ_-beJ0u3mLPN_PS3fHJ8ZrczgccfEf8zeZbBpXM33J80JEbaMb7qSfux0ebPmln6vh18COGO34V0M78YnRkZz-N8QV75rCPdHbYp-z6y-er-mt2-f38ov5wmdkChMx0WWmhRCulMcY6mWsFuVPSgZYWyxY6JQArKqWulEbhFACCNkbkXZWOxSl7tffdhenXQnFuBh8t9T2ONC2x0SJFgKgS8f2eaMMUYyDX7IIf0usNiOax_uYf9TdSNan-5PDyELW0A3VH_aHshG_2-M844w0dcQyztz39z17vR0o5su0WQ0Nj8RfT0qWz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80846106</pqid></control><display><type>article</type><title>Double-Blind Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole in Complicated Urinary Tract Infections</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>ISHIGAMI, Joji ; KAMIDONO, Sadao ; ARAKAWA, Sohichi ; KATAOKA, Nobumasa ; NAKANO, Koji ; HARADA, Masuyoshi ; HIROOKA, Kyubei ; SHIMATANI, Nobori ; ITANI, Atsushi ; MATSUSHITA, Masami ; HIKOSAKA, Koji ; MATSUMOTO, Osamu ; OHYA, Kakuyoshi ; ITO, Noboru ; HARADA, Kenji ; KIYOTA, Toshikazu ; SAITO, Hiroshi ; KITANO, Yoshihiko ; TAKAHASHI, Yasumasa ; HARA, Shinji ; OHMAE, Hiroshi ; OHBE, Toru ; YASUNO, Hirohiko ; KATAOKA, Nobuo ; OKUDAIRA, Hiroshi ; KAWABATA, Gaku ; OHSHIMA, Hideo ; DEN, Shusoo ; TOMIOKA, Osamu ; TADERA, Shigenori ; UEHARAGUCHI, Hiroshi ; ODA, Yoshinori ; YAMAZAKI, Hiroshi ; TAKADA, Kenichi ; OKADA, Yasunaga ; HINENO, Suguru ; KURODA, Yasuji ; MOMOSE, Shunro ; TAKEI, Mineo ; KUMAZAWA, Joichi ; NAKAMUTA, Seiichi ; SAKAMOTO, Kimitaka ; OSHIMA, Kazuhiro ; ISHIZAWA, Nobuyuki ; OSADA, Yukio ; HARA, Sanshin ; EMOTO, Kanichi ; HIRATA, Kozo ; MORITA, Ichikiro ; MINODA, Kunihiro ; HIRANO, Haruka ; NAGAYOSHI, Hiroyuki ; SATO, Shinichi ; OMOTO, Tetsuo ; YAGI, Hiroaki ; HIRATA, Hiroshi ; ANDO, Sadamu ; IWATSUBO, Eiji ; KOMINE, Shinichiro ; OGAWA, Nobuya</creator><creatorcontrib>ISHIGAMI, Joji ; KAMIDONO, Sadao ; ARAKAWA, Sohichi ; KATAOKA, Nobumasa ; NAKANO, Koji ; HARADA, Masuyoshi ; HIROOKA, Kyubei ; SHIMATANI, Nobori ; ITANI, Atsushi ; MATSUSHITA, Masami ; HIKOSAKA, Koji ; MATSUMOTO, Osamu ; OHYA, Kakuyoshi ; ITO, Noboru ; HARADA, Kenji ; KIYOTA, Toshikazu ; SAITO, Hiroshi ; KITANO, Yoshihiko ; TAKAHASHI, Yasumasa ; HARA, Shinji ; OHMAE, Hiroshi ; OHBE, Toru ; YASUNO, Hirohiko ; KATAOKA, Nobuo ; OKUDAIRA, Hiroshi ; KAWABATA, Gaku ; OHSHIMA, Hideo ; DEN, Shusoo ; TOMIOKA, Osamu ; TADERA, Shigenori ; UEHARAGUCHI, Hiroshi ; ODA, Yoshinori ; YAMAZAKI, Hiroshi ; TAKADA, Kenichi ; OKADA, Yasunaga ; HINENO, Suguru ; KURODA, Yasuji ; MOMOSE, Shunro ; TAKEI, Mineo ; KUMAZAWA, Joichi ; NAKAMUTA, Seiichi ; SAKAMOTO, Kimitaka ; OSHIMA, Kazuhiro ; ISHIZAWA, Nobuyuki ; OSADA, Yukio ; HARA, Sanshin ; EMOTO, Kanichi ; HIRATA, Kozo ; MORITA, Ichikiro ; MINODA, Kunihiro ; HIRANO, Haruka ; NAGAYOSHI, Hiroyuki ; SATO, Shinichi ; OMOTO, Tetsuo ; YAGI, Hiroaki ; HIRATA, Hiroshi ; ANDO, Sadamu ; IWATSUBO, Eiji ; KOMINE, Shinichiro ; OGAWA, Nobuya</creatorcontrib><description>The clinical efficacy and safety of cefpiramide (SM-1652, CPM) were compared with those of cefmetazole (CMZ) in patients with complicated urinary tract infections by double-blind method. Either of CPM or CMZ was assigned to each patient at random. Administration was performed by intravenous drip infusion for a fixed period of 5 days and daily dosage was fixed at each 2 g for CPM or CMZ. Out of 249 patients, 211 patients (CPM; 110 cases, CMZ: 101 cases) were evaluated for clinical efficacy by the criteria proposed by UTI committee in Japan. It was indicated that there was no significant difference between the two groups (CPM group and CMZ group) regarding the all of background factors. Overall clinical effectiveness; Response was excellent in 27.7%, moderate in 39.8% and poor in 32.5% of the CPM group, excellent in 17.3%, moderate in 33.3% and poor in 49.3% of the CMZ group. Response rate inclusive of excellent and moderate was significantly higher in the CPM group than in the CMZ (p<0.05). Effect on pyuria; Rate of improvement (Cleared and Decreased) on pyuria was 44.6% in the CPM group and 36.0% in the CMZ group. There was no significant difference between the two groups. Effect on bacteriuria; Rate of improvement (Eliminated and Decreased) on bacteriuria was 60.2% in the CPM group and 46.7% in the CMZ group. There was no significant difference between the two groups. Bacteriological response; The eradication rate for all organisms isolated before treatment was 75.8% in the CPM group and 80.2% in the CMZ group. There was no significant difference between the two groups. The incidence rate of side effects and abnormal laboratory findings were 2 cases (eruption 2) and 3 cases (elevation of transaminase), respectively in the CPM group and 1 case (itching and pericheiloparalysis) and 4 cases (elevation of transaminase or BUN), respectively in the CMZ group, with no significant differences between the two groups. These results indicate that CPM is a useful drug for the treatment of complicated urinary tract infections.</description><identifier>ISSN: 0387-5911</identifier><identifier>EISSN: 1884-569X</identifier><identifier>DOI: 10.11150/kansenshogakuzasshi1970.57.695</identifier><identifier>PMID: 6420483</identifier><language>eng ; jpn</language><publisher>Japan: The Japanese Association for Infectious Diseases</publisher><subject>A new cephem antibiotics ; Adolescent ; Adult ; Aged ; Cefmetazole ; Cefpiramide (CPM, SM-1652) ; Cephalosporins - therapeutic use ; Cephamycins - therapeutic use ; Clinical Trials as Topic ; Double-blind comparative study ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Urinary tract infection ; Urinary Tract Infections - drug therapy</subject><ispartof>Kansenshogaku Zasshi, 1983/08/20, Vol.57(8), pp.695-723</ispartof><rights>The Japansese Association for Infectious Diseases</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1876,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6420483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ISHIGAMI, Joji</creatorcontrib><creatorcontrib>KAMIDONO, Sadao</creatorcontrib><creatorcontrib>ARAKAWA, Sohichi</creatorcontrib><creatorcontrib>KATAOKA, Nobumasa</creatorcontrib><creatorcontrib>NAKANO, Koji</creatorcontrib><creatorcontrib>HARADA, Masuyoshi</creatorcontrib><creatorcontrib>HIROOKA, Kyubei</creatorcontrib><creatorcontrib>SHIMATANI, Nobori</creatorcontrib><creatorcontrib>ITANI, Atsushi</creatorcontrib><creatorcontrib>MATSUSHITA, Masami</creatorcontrib><creatorcontrib>HIKOSAKA, Koji</creatorcontrib><creatorcontrib>MATSUMOTO, Osamu</creatorcontrib><creatorcontrib>OHYA, Kakuyoshi</creatorcontrib><creatorcontrib>ITO, Noboru</creatorcontrib><creatorcontrib>HARADA, Kenji</creatorcontrib><creatorcontrib>KIYOTA, Toshikazu</creatorcontrib><creatorcontrib>SAITO, Hiroshi</creatorcontrib><creatorcontrib>KITANO, Yoshihiko</creatorcontrib><creatorcontrib>TAKAHASHI, Yasumasa</creatorcontrib><creatorcontrib>HARA, Shinji</creatorcontrib><creatorcontrib>OHMAE, Hiroshi</creatorcontrib><creatorcontrib>OHBE, Toru</creatorcontrib><creatorcontrib>YASUNO, Hirohiko</creatorcontrib><creatorcontrib>KATAOKA, Nobuo</creatorcontrib><creatorcontrib>OKUDAIRA, Hiroshi</creatorcontrib><creatorcontrib>KAWABATA, Gaku</creatorcontrib><creatorcontrib>OHSHIMA, Hideo</creatorcontrib><creatorcontrib>DEN, Shusoo</creatorcontrib><creatorcontrib>TOMIOKA, Osamu</creatorcontrib><creatorcontrib>TADERA, Shigenori</creatorcontrib><creatorcontrib>UEHARAGUCHI, Hiroshi</creatorcontrib><creatorcontrib>ODA, Yoshinori</creatorcontrib><creatorcontrib>YAMAZAKI, Hiroshi</creatorcontrib><creatorcontrib>TAKADA, Kenichi</creatorcontrib><creatorcontrib>OKADA, Yasunaga</creatorcontrib><creatorcontrib>HINENO, Suguru</creatorcontrib><creatorcontrib>KURODA, Yasuji</creatorcontrib><creatorcontrib>MOMOSE, Shunro</creatorcontrib><creatorcontrib>TAKEI, Mineo</creatorcontrib><creatorcontrib>KUMAZAWA, Joichi</creatorcontrib><creatorcontrib>NAKAMUTA, Seiichi</creatorcontrib><creatorcontrib>SAKAMOTO, Kimitaka</creatorcontrib><creatorcontrib>OSHIMA, Kazuhiro</creatorcontrib><creatorcontrib>ISHIZAWA, Nobuyuki</creatorcontrib><creatorcontrib>OSADA, Yukio</creatorcontrib><creatorcontrib>HARA, Sanshin</creatorcontrib><creatorcontrib>EMOTO, Kanichi</creatorcontrib><creatorcontrib>HIRATA, Kozo</creatorcontrib><creatorcontrib>MORITA, Ichikiro</creatorcontrib><creatorcontrib>MINODA, Kunihiro</creatorcontrib><creatorcontrib>HIRANO, Haruka</creatorcontrib><creatorcontrib>NAGAYOSHI, Hiroyuki</creatorcontrib><creatorcontrib>SATO, Shinichi</creatorcontrib><creatorcontrib>OMOTO, Tetsuo</creatorcontrib><creatorcontrib>YAGI, Hiroaki</creatorcontrib><creatorcontrib>HIRATA, Hiroshi</creatorcontrib><creatorcontrib>ANDO, Sadamu</creatorcontrib><creatorcontrib>IWATSUBO, Eiji</creatorcontrib><creatorcontrib>KOMINE, Shinichiro</creatorcontrib><creatorcontrib>OGAWA, Nobuya</creatorcontrib><title>Double-Blind Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole in Complicated Urinary Tract Infections</title><title>Kansenshogaku Zasshi</title><addtitle>J. J. A. Inf. D</addtitle><description>The clinical efficacy and safety of cefpiramide (SM-1652, CPM) were compared with those of cefmetazole (CMZ) in patients with complicated urinary tract infections by double-blind method. Either of CPM or CMZ was assigned to each patient at random. Administration was performed by intravenous drip infusion for a fixed period of 5 days and daily dosage was fixed at each 2 g for CPM or CMZ. Out of 249 patients, 211 patients (CPM; 110 cases, CMZ: 101 cases) were evaluated for clinical efficacy by the criteria proposed by UTI committee in Japan. It was indicated that there was no significant difference between the two groups (CPM group and CMZ group) regarding the all of background factors. Overall clinical effectiveness; Response was excellent in 27.7%, moderate in 39.8% and poor in 32.5% of the CPM group, excellent in 17.3%, moderate in 33.3% and poor in 49.3% of the CMZ group. Response rate inclusive of excellent and moderate was significantly higher in the CPM group than in the CMZ (p<0.05). Effect on pyuria; Rate of improvement (Cleared and Decreased) on pyuria was 44.6% in the CPM group and 36.0% in the CMZ group. There was no significant difference between the two groups. Effect on bacteriuria; Rate of improvement (Eliminated and Decreased) on bacteriuria was 60.2% in the CPM group and 46.7% in the CMZ group. There was no significant difference between the two groups. Bacteriological response; The eradication rate for all organisms isolated before treatment was 75.8% in the CPM group and 80.2% in the CMZ group. There was no significant difference between the two groups. The incidence rate of side effects and abnormal laboratory findings were 2 cases (eruption 2) and 3 cases (elevation of transaminase), respectively in the CPM group and 1 case (itching and pericheiloparalysis) and 4 cases (elevation of transaminase or BUN), respectively in the CMZ group, with no significant differences between the two groups. These results indicate that CPM is a useful drug for the treatment of complicated urinary tract infections.</description><subject>A new cephem antibiotics</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Cefmetazole</subject><subject>Cefpiramide (CPM, SM-1652)</subject><subject>Cephalosporins - therapeutic use</subject><subject>Cephamycins - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Double-blind comparative study</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Urinary tract infection</subject><subject>Urinary Tract Infections - drug therapy</subject><issn>0387-5911</issn><issn>1884-569X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UEtv1DAQthCorEp_ApJPPA5ZPEkc2ycEAUqlIg7bStyiiTPumuax2Ami_fW43dXe4DIjzfcafYy9BrEGACne3eIYaYzb6QZvl3uMcevBKLGWal0Z-YStQOsyk5X58ZStRKFVJg3Ac3YWo2-FEKYUucxP2ElV5qLUxYr9-TQtbU_Zx96PHa-nYYcBZ_-beJ0u3mLPN_PS3fHJ8ZrczgccfEf8zeZbBpXM33J80JEbaMb7qSfux0ebPmln6vh18COGO34V0M78YnRkZz-N8QV75rCPdHbYp-z6y-er-mt2-f38ov5wmdkChMx0WWmhRCulMcY6mWsFuVPSgZYWyxY6JQArKqWulEbhFACCNkbkXZWOxSl7tffdhenXQnFuBh8t9T2ONC2x0SJFgKgS8f2eaMMUYyDX7IIf0usNiOax_uYf9TdSNan-5PDyELW0A3VH_aHshG_2-M844w0dcQyztz39z17vR0o5su0WQ0Nj8RfT0qWz</recordid><startdate>198308</startdate><enddate>198308</enddate><creator>ISHIGAMI, Joji</creator><creator>KAMIDONO, Sadao</creator><creator>ARAKAWA, Sohichi</creator><creator>KATAOKA, Nobumasa</creator><creator>NAKANO, Koji</creator><creator>HARADA, Masuyoshi</creator><creator>HIROOKA, Kyubei</creator><creator>SHIMATANI, Nobori</creator><creator>ITANI, Atsushi</creator><creator>MATSUSHITA, Masami</creator><creator>HIKOSAKA, Koji</creator><creator>MATSUMOTO, Osamu</creator><creator>OHYA, Kakuyoshi</creator><creator>ITO, Noboru</creator><creator>HARADA, Kenji</creator><creator>KIYOTA, Toshikazu</creator><creator>SAITO, Hiroshi</creator><creator>KITANO, Yoshihiko</creator><creator>TAKAHASHI, Yasumasa</creator><creator>HARA, Shinji</creator><creator>OHMAE, Hiroshi</creator><creator>OHBE, Toru</creator><creator>YASUNO, Hirohiko</creator><creator>KATAOKA, Nobuo</creator><creator>OKUDAIRA, Hiroshi</creator><creator>KAWABATA, Gaku</creator><creator>OHSHIMA, Hideo</creator><creator>DEN, Shusoo</creator><creator>TOMIOKA, Osamu</creator><creator>TADERA, Shigenori</creator><creator>UEHARAGUCHI, Hiroshi</creator><creator>ODA, Yoshinori</creator><creator>YAMAZAKI, Hiroshi</creator><creator>TAKADA, Kenichi</creator><creator>OKADA, Yasunaga</creator><creator>HINENO, Suguru</creator><creator>KURODA, Yasuji</creator><creator>MOMOSE, Shunro</creator><creator>TAKEI, Mineo</creator><creator>KUMAZAWA, Joichi</creator><creator>NAKAMUTA, Seiichi</creator><creator>SAKAMOTO, Kimitaka</creator><creator>OSHIMA, Kazuhiro</creator><creator>ISHIZAWA, Nobuyuki</creator><creator>OSADA, Yukio</creator><creator>HARA, Sanshin</creator><creator>EMOTO, Kanichi</creator><creator>HIRATA, Kozo</creator><creator>MORITA, Ichikiro</creator><creator>MINODA, Kunihiro</creator><creator>HIRANO, Haruka</creator><creator>NAGAYOSHI, Hiroyuki</creator><creator>SATO, Shinichi</creator><creator>OMOTO, Tetsuo</creator><creator>YAGI, Hiroaki</creator><creator>HIRATA, Hiroshi</creator><creator>ANDO, Sadamu</creator><creator>IWATSUBO, Eiji</creator><creator>KOMINE, Shinichiro</creator><creator>OGAWA, Nobuya</creator><general>The Japanese Association for Infectious Diseases</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198308</creationdate><title>Double-Blind Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole in Complicated Urinary Tract Infections</title><author>ISHIGAMI, Joji ; KAMIDONO, Sadao ; ARAKAWA, Sohichi ; KATAOKA, Nobumasa ; NAKANO, Koji ; HARADA, Masuyoshi ; HIROOKA, Kyubei ; SHIMATANI, Nobori ; ITANI, Atsushi ; MATSUSHITA, Masami ; HIKOSAKA, Koji ; MATSUMOTO, Osamu ; OHYA, Kakuyoshi ; ITO, Noboru ; HARADA, Kenji ; KIYOTA, Toshikazu ; SAITO, Hiroshi ; KITANO, Yoshihiko ; TAKAHASHI, Yasumasa ; HARA, Shinji ; OHMAE, Hiroshi ; OHBE, Toru ; YASUNO, Hirohiko ; KATAOKA, Nobuo ; OKUDAIRA, Hiroshi ; KAWABATA, Gaku ; OHSHIMA, Hideo ; DEN, Shusoo ; TOMIOKA, Osamu ; TADERA, Shigenori ; UEHARAGUCHI, Hiroshi ; ODA, Yoshinori ; YAMAZAKI, Hiroshi ; TAKADA, Kenichi ; OKADA, Yasunaga ; HINENO, Suguru ; KURODA, Yasuji ; MOMOSE, Shunro ; TAKEI, Mineo ; KUMAZAWA, Joichi ; NAKAMUTA, Seiichi ; SAKAMOTO, Kimitaka ; OSHIMA, Kazuhiro ; ISHIZAWA, Nobuyuki ; OSADA, Yukio ; HARA, Sanshin ; EMOTO, Kanichi ; HIRATA, Kozo ; MORITA, Ichikiro ; MINODA, Kunihiro ; HIRANO, Haruka ; NAGAYOSHI, Hiroyuki ; SATO, Shinichi ; OMOTO, Tetsuo ; YAGI, Hiroaki ; HIRATA, Hiroshi ; ANDO, Sadamu ; IWATSUBO, Eiji ; KOMINE, Shinichiro ; OGAWA, Nobuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3105-8468070b55999cf528712f75f185ca4b1d701a6e458678a0f711a189902d64583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>1983</creationdate><topic>A new cephem antibiotics</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Cefmetazole</topic><topic>Cefpiramide (CPM, SM-1652)</topic><topic>Cephalosporins - therapeutic use</topic><topic>Cephamycins - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Double-blind comparative study</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Urinary tract infection</topic><topic>Urinary Tract Infections - drug therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>ISHIGAMI, Joji</creatorcontrib><creatorcontrib>KAMIDONO, Sadao</creatorcontrib><creatorcontrib>ARAKAWA, Sohichi</creatorcontrib><creatorcontrib>KATAOKA, Nobumasa</creatorcontrib><creatorcontrib>NAKANO, Koji</creatorcontrib><creatorcontrib>HARADA, Masuyoshi</creatorcontrib><creatorcontrib>HIROOKA, Kyubei</creatorcontrib><creatorcontrib>SHIMATANI, Nobori</creatorcontrib><creatorcontrib>ITANI, Atsushi</creatorcontrib><creatorcontrib>MATSUSHITA, Masami</creatorcontrib><creatorcontrib>HIKOSAKA, Koji</creatorcontrib><creatorcontrib>MATSUMOTO, Osamu</creatorcontrib><creatorcontrib>OHYA, Kakuyoshi</creatorcontrib><creatorcontrib>ITO, Noboru</creatorcontrib><creatorcontrib>HARADA, Kenji</creatorcontrib><creatorcontrib>KIYOTA, Toshikazu</creatorcontrib><creatorcontrib>SAITO, Hiroshi</creatorcontrib><creatorcontrib>KITANO, Yoshihiko</creatorcontrib><creatorcontrib>TAKAHASHI, Yasumasa</creatorcontrib><creatorcontrib>HARA, Shinji</creatorcontrib><creatorcontrib>OHMAE, Hiroshi</creatorcontrib><creatorcontrib>OHBE, Toru</creatorcontrib><creatorcontrib>YASUNO, Hirohiko</creatorcontrib><creatorcontrib>KATAOKA, Nobuo</creatorcontrib><creatorcontrib>OKUDAIRA, Hiroshi</creatorcontrib><creatorcontrib>KAWABATA, Gaku</creatorcontrib><creatorcontrib>OHSHIMA, Hideo</creatorcontrib><creatorcontrib>DEN, Shusoo</creatorcontrib><creatorcontrib>TOMIOKA, Osamu</creatorcontrib><creatorcontrib>TADERA, Shigenori</creatorcontrib><creatorcontrib>UEHARAGUCHI, Hiroshi</creatorcontrib><creatorcontrib>ODA, Yoshinori</creatorcontrib><creatorcontrib>YAMAZAKI, Hiroshi</creatorcontrib><creatorcontrib>TAKADA, Kenichi</creatorcontrib><creatorcontrib>OKADA, Yasunaga</creatorcontrib><creatorcontrib>HINENO, Suguru</creatorcontrib><creatorcontrib>KURODA, Yasuji</creatorcontrib><creatorcontrib>MOMOSE, Shunro</creatorcontrib><creatorcontrib>TAKEI, Mineo</creatorcontrib><creatorcontrib>KUMAZAWA, Joichi</creatorcontrib><creatorcontrib>NAKAMUTA, Seiichi</creatorcontrib><creatorcontrib>SAKAMOTO, Kimitaka</creatorcontrib><creatorcontrib>OSHIMA, Kazuhiro</creatorcontrib><creatorcontrib>ISHIZAWA, Nobuyuki</creatorcontrib><creatorcontrib>OSADA, Yukio</creatorcontrib><creatorcontrib>HARA, Sanshin</creatorcontrib><creatorcontrib>EMOTO, Kanichi</creatorcontrib><creatorcontrib>HIRATA, Kozo</creatorcontrib><creatorcontrib>MORITA, Ichikiro</creatorcontrib><creatorcontrib>MINODA, Kunihiro</creatorcontrib><creatorcontrib>HIRANO, Haruka</creatorcontrib><creatorcontrib>NAGAYOSHI, Hiroyuki</creatorcontrib><creatorcontrib>SATO, Shinichi</creatorcontrib><creatorcontrib>OMOTO, Tetsuo</creatorcontrib><creatorcontrib>YAGI, Hiroaki</creatorcontrib><creatorcontrib>HIRATA, Hiroshi</creatorcontrib><creatorcontrib>ANDO, Sadamu</creatorcontrib><creatorcontrib>IWATSUBO, Eiji</creatorcontrib><creatorcontrib>KOMINE, Shinichiro</creatorcontrib><creatorcontrib>OGAWA, Nobuya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Kansenshogaku Zasshi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ISHIGAMI, Joji</au><au>KAMIDONO, Sadao</au><au>ARAKAWA, Sohichi</au><au>KATAOKA, Nobumasa</au><au>NAKANO, Koji</au><au>HARADA, Masuyoshi</au><au>HIROOKA, Kyubei</au><au>SHIMATANI, Nobori</au><au>ITANI, Atsushi</au><au>MATSUSHITA, Masami</au><au>HIKOSAKA, Koji</au><au>MATSUMOTO, Osamu</au><au>OHYA, Kakuyoshi</au><au>ITO, Noboru</au><au>HARADA, Kenji</au><au>KIYOTA, Toshikazu</au><au>SAITO, Hiroshi</au><au>KITANO, Yoshihiko</au><au>TAKAHASHI, Yasumasa</au><au>HARA, Shinji</au><au>OHMAE, Hiroshi</au><au>OHBE, Toru</au><au>YASUNO, Hirohiko</au><au>KATAOKA, Nobuo</au><au>OKUDAIRA, Hiroshi</au><au>KAWABATA, Gaku</au><au>OHSHIMA, Hideo</au><au>DEN, Shusoo</au><au>TOMIOKA, Osamu</au><au>TADERA, Shigenori</au><au>UEHARAGUCHI, Hiroshi</au><au>ODA, Yoshinori</au><au>YAMAZAKI, Hiroshi</au><au>TAKADA, Kenichi</au><au>OKADA, Yasunaga</au><au>HINENO, Suguru</au><au>KURODA, Yasuji</au><au>MOMOSE, Shunro</au><au>TAKEI, Mineo</au><au>KUMAZAWA, Joichi</au><au>NAKAMUTA, Seiichi</au><au>SAKAMOTO, Kimitaka</au><au>OSHIMA, Kazuhiro</au><au>ISHIZAWA, Nobuyuki</au><au>OSADA, Yukio</au><au>HARA, Sanshin</au><au>EMOTO, Kanichi</au><au>HIRATA, Kozo</au><au>MORITA, Ichikiro</au><au>MINODA, Kunihiro</au><au>HIRANO, Haruka</au><au>NAGAYOSHI, Hiroyuki</au><au>SATO, Shinichi</au><au>OMOTO, Tetsuo</au><au>YAGI, Hiroaki</au><au>HIRATA, Hiroshi</au><au>ANDO, Sadamu</au><au>IWATSUBO, Eiji</au><au>KOMINE, Shinichiro</au><au>OGAWA, Nobuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Double-Blind Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole in Complicated Urinary Tract Infections</atitle><jtitle>Kansenshogaku Zasshi</jtitle><addtitle>J. J. A. Inf. D</addtitle><date>1983-08</date><risdate>1983</risdate><volume>57</volume><issue>8</issue><spage>695</spage><epage>723</epage><pages>695-723</pages><issn>0387-5911</issn><eissn>1884-569X</eissn><abstract>The clinical efficacy and safety of cefpiramide (SM-1652, CPM) were compared with those of cefmetazole (CMZ) in patients with complicated urinary tract infections by double-blind method. Either of CPM or CMZ was assigned to each patient at random. Administration was performed by intravenous drip infusion for a fixed period of 5 days and daily dosage was fixed at each 2 g for CPM or CMZ. Out of 249 patients, 211 patients (CPM; 110 cases, CMZ: 101 cases) were evaluated for clinical efficacy by the criteria proposed by UTI committee in Japan. It was indicated that there was no significant difference between the two groups (CPM group and CMZ group) regarding the all of background factors. Overall clinical effectiveness; Response was excellent in 27.7%, moderate in 39.8% and poor in 32.5% of the CPM group, excellent in 17.3%, moderate in 33.3% and poor in 49.3% of the CMZ group. Response rate inclusive of excellent and moderate was significantly higher in the CPM group than in the CMZ (p<0.05). Effect on pyuria; Rate of improvement (Cleared and Decreased) on pyuria was 44.6% in the CPM group and 36.0% in the CMZ group. There was no significant difference between the two groups. Effect on bacteriuria; Rate of improvement (Eliminated and Decreased) on bacteriuria was 60.2% in the CPM group and 46.7% in the CMZ group. There was no significant difference between the two groups. Bacteriological response; The eradication rate for all organisms isolated before treatment was 75.8% in the CPM group and 80.2% in the CMZ group. There was no significant difference between the two groups. The incidence rate of side effects and abnormal laboratory findings were 2 cases (eruption 2) and 3 cases (elevation of transaminase), respectively in the CPM group and 1 case (itching and pericheiloparalysis) and 4 cases (elevation of transaminase or BUN), respectively in the CMZ group, with no significant differences between the two groups. These results indicate that CPM is a useful drug for the treatment of complicated urinary tract infections.</abstract><cop>Japan</cop><pub>The Japanese Association for Infectious Diseases</pub><pmid>6420483</pmid><doi>10.11150/kansenshogakuzasshi1970.57.695</doi><tpages>29</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0387-5911 |
| ispartof | Kansenshogaku Zasshi, 1983/08/20, Vol.57(8), pp.695-723 |
| issn | 0387-5911 1884-569X |
| language | eng ; jpn |
| recordid | cdi_proquest_miscellaneous_80846106 |
| source | J-STAGE Free; MEDLINE; Alma/SFX Local Collection |
| subjects | A new cephem antibiotics Adolescent Adult Aged Cefmetazole Cefpiramide (CPM, SM-1652) Cephalosporins - therapeutic use Cephamycins - therapeutic use Clinical Trials as Topic Double-blind comparative study Double-Blind Method Female Humans Male Middle Aged Urinary tract infection Urinary Tract Infections - drug therapy |
| title | Double-Blind Comparative Clinical Study of Cefpiramide (SM-1652) and Cefmetazole in Complicated Urinary Tract Infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A59%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Double-Blind%20Comparative%20Clinical%20Study%20of%20Cefpiramide%20(SM-1652)%20and%20Cefmetazole%20in%20Complicated%20Urinary%20Tract%20Infections&rft.jtitle=Kansenshogaku%20Zasshi&rft.au=ISHIGAMI,%20Joji&rft.date=1983-08&rft.volume=57&rft.issue=8&rft.spage=695&rft.epage=723&rft.pages=695-723&rft.issn=0387-5911&rft.eissn=1884-569X&rft_id=info:doi/10.11150/kansenshogakuzasshi1970.57.695&rft_dat=%3Cproquest_cross%3E80846106%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80846106&rft_id=info:pmid/6420483&rfr_iscdi=true |